The Russian Ministry of Industry and Trade Ministry has announced a tender for the production of five imported drugs, which are not produced by domestic manufacturers, and are not protected by patents of foreign companies in Russia.
Among these drugs are gadodiamide and iohexol (both diagnostic contrast media agents), propofol, a drug that reduces anxiety and tension, and promotes relaxation and sleep or loss of consciousness, as well as ropivacaine, and sevoflurane, which are used for anesthesia. All of the drugs are considered as life-saving.
Under the terms of the tender, the government plans to allocate 18 million rubles (around $650,000) for the development of technology and organization of production per each lot. Tenders are expected to be held on August 3.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze